Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from RBC Capital Markets

7 Coupa Software Analysts React To Q1 Earnings Beat: 'Lots Of Noise Around Billings'

Coupa Software Inc (NASDAQ: COUP) shares traded higher by 1.8% on Tuesday after the company reported strong earnings numbers and record subscription revenues in the first quarter.

Benzinga

5 CrowdStrike Analysts React To Q1 Earnings Beat, Guidance Hike, Potential Hiring Ramp

CrowdStrike Holdings Inc (NASDAQ: CRWD) shares traded down by 6.2% on Friday after the company reported a first-quarter earnings beat and raised its full-year guidance.

Benzinga

9 Salesforce Analysts React To Q1 Earnings Beat: 'Next Quality Software GARP Stock'

Salesforce Inc (NYSE: CRM) shares jumped Wednesday morning after the company reported first-quarter earnings and raised its profit forecast.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Danaher's Defensive Portfolio Is Ideal Amid Macro Fears: RBC Analyst

Danaher Corporation’s (NYSE: DHR) portfolio, with 75% recurring revenues and more than a 90% mix in life sciences and diagnostics, appears “incrementally more attractive” amid the currently harsh macro environment, according to RBC Capital Markets.

Benzinga

RBC Capital Slashes Verrica's Price Target After Third Rejection - What's Next?

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) was slapped with a third FDA rejection for YCANTH (VP-102) as general contract manufacturing organization challenges continue to plague the approval. RBC Capital Markets has downgraded the stock to Sector Perform from Outperform and lowered the price target from $16 to $4. The analysts note that the issues fall outside of…

Benzinga

Advance Auto Parts Q1 Earnings: Initial Takeaways Of 3 Top Analysts

Advance Auto Parts, Inc. (NYSE: AAP) reported fiscal first-quarter revenues and earnings of $3.37 billion and $3.57 per share, respectively, marginally missing Street expectations on both metrics.

Benzinga

A Warning Sign For Other Advertisers? Snapchat Analysts React To Shocking Guidance Cut, Stock Sell-Off

Snap Inc (NYSE: SNAP) shares are plummeting 40% after CEO Evan Spiegel warned employees the company will miss its targets for revenue and earnings in the second quarter.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

RBC Capital Sees Meaningful M&A Execution For This Critical Care-Focused Stock

Teleflex Inc (NYSE: TFX) hosted its Investor Day and issued plans for 2023-2025. RBC Capital Markets believe TFX is a stronger company delivering stable revenue growth in the M-HSDs, margin expansion, double-digit EPS growth, and strong FCF.

Benzinga

5 Walmart Analysts React To Mixed Q1 Earnings: 'Particularly Attractive Buying Opportunity'

Walmart Inc (NYSE: WMT) shares were in the clearance aisle Wednesday after the company reported rising costs related to supply chain problems and inflation in the first quarter.

Benzinga

Uber Adds Charter Buses To Its US App

Uber Technologies, Inc (NYSE:UBER) forged a collaboration to allow its users to charter private buses and coaches through its app, the Financial Times reports. The option targets weddings or wine tours across the U.S., helping Uber expand beyond its core ride-share business. U.S. Coachways, one of the country’s most extensive bus chartering…

Benzinga

Rivian Is A 'Show-Me-The-Money' Story But Has 'More Pieces In Place' Than Peers: Analysts React To Q1 Earnings

Electric vehicle company Rivian Automotive Inc (NASDAQ: RIVN) reported first-quarter production of 2,553 vehicles. The company delivered 1,227 vehicles in the first quarter and reported more than 90,000 net pre-orders of its Rivian R1 electric pickup truck.

Benzinga

7 Walt Disney Analysts React To Q2 Earnings Miss, Subscriber Beat, Ongoing Asia Weakness

Walt Disney Co (NYSE: DIS) shares traded lower by 3.7% on Thursday after the company reported first-quarter earnings and said ongoing COVID-19 disruptions are weighing on its Asia theme park business.

Benzinga

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and has little conviction in BCMA/CD70 data within weeks. The analysts lowered its price target to $85 from $95 to reflect higher Opex, with a Sector Perform rating. As recently…

Benzinga

RBC Capital: What To Expect When Bausch Health Companies Reports Q1 Tomorrow

RBC Capital Markets expects Bausch Health Companies Inc (NYSE: BHC) Q1 FY22 revenue of $2.02 billion (previous $2.04 billion; consensus $2.05 billion) and adjusted EBITDA of $799 million (previous $816 million; consensus $819 million).

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value

RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet.

Benzinga

Why This Analyst Thinks Tabula Rasa's Divestiture Plans 'An Important Step'

RBC Capital Markets believe that the market has been assigning little-to-no value to Tabula Rasa HealthCare Inc's (NASDAQ: TRHC) MedWise, which has been burning cash and clouding, a strong core PACE business.

Benzinga

Analysts Expect Clarity Imminent On Intercept's NASH Story

RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA) in NASH, with REGENERATE re-analyses on deck, REVERSE reading in the next quarter. The analysts say it remains challenging to get visibility on how the efficacy/safety analyses will look,…

Benzinga

'Still A Second-Half Story': Twilio Analysts React To Mixed Q1 Earnings

Twilio Inc (NYSE: TWLO) shares dropped 2.7% on Thursday after the company reported conservative second-quarter guidance.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Lyft Analysts React To Q2 Guidance Miss, Heavy Investments In Lagging Driver Recovery

LYFT Inc (NASDAQ: LYFT) shares plummeted 32% on Wednesday after the company issued second-quarter guidance that came up well short of market expectations.

Benzinga

Here's Why This Analyst Cut Price Target On Regeneron

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

Benzinga

Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock

RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in the space could drive appreciation.

Benzinga

Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales

Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.

Benzinga

Why These Analysts Cut Price Target On Teleflex

RBC Capital Markets says that Teleflex Incorporated (NYSE: TFX) delivered a Q1 beat and maintained 2022 guidance.

Benzinga

'Long Road Of Rebuilding Begins': PayPal Analysts React To Mixed Q1 Earnings Report

Shares of PayPal Holdings Inc (NASDAQ: PYPL) gained 11% on Thursday after the company reported a revenue beat but cut its 2022 guidance.

Benzinga

Teladoc Analysts React To Shocking Q1 Losses, Rising BetterHelp Costs

A brutal 12 months for Teladoc Health Inc (NYSE: TDOC) went from bad to much worse on Thursday when the stock dropped another 43% after the company reported much larger-than-expected losses in the first quarter and slashed its 2022 guidance.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.